Monument Therapeutics Reports Positive Phase I Results for Novel Cognitive Impairment Associated with Schizophrenia Treatment 23 Jun Written By Alexandra Collingbourne Alexandra Collingbourne
Monument Therapeutics Reports Positive Phase I Results for Novel Cognitive Impairment Associated with Schizophrenia Treatment 23 Jun Written By Alexandra Collingbourne Alexandra Collingbourne